These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 34011336

  • 21. Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
    Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, Reed-Guy L, Bleiberg B, Sun L, Singh A, Cohen RB, Aggarwal C, Marmarelis M, Langer C.
    Lung Cancer; 2024 Sep; 195():107926. PubMed ID: 39137595
    [Abstract] [Full Text] [Related]

  • 22. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
    Vaid AK, Gupta A, Momi G.
    Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
    [Abstract] [Full Text] [Related]

  • 23. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.
    Chen HY, Chen CH, Liao WC, Lin YC, Chen HJ, Hsia TC, Cheng WC, Tu CY.
    BMC Pulm Med; 2024 Oct 16; 24(1):517. PubMed ID: 39415161
    [Abstract] [Full Text] [Related]

  • 24. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Tozuka T, Noro R, Mizutani H, Kurimoto F, Hakozaki T, Hisakane K, Naito T, Takahashi S, Taniuchi N, Yajima C, Hosomi Y, Hirose T, Minegishi Y, Okano T, Kamio K, Yamaguchi T, Seike M, East Japan Chesters Group.
    Lung Cancer; 2024 May 16; 191():107540. PubMed ID: 38614069
    [Abstract] [Full Text] [Related]

  • 25. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS.
    Target Oncol; 2021 Mar 16; 16(2):165-176. PubMed ID: 33544337
    [Abstract] [Full Text] [Related]

  • 26. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.
    Lung Cancer; 2019 Jan 16; 127():96-102. PubMed ID: 30642559
    [Abstract] [Full Text] [Related]

  • 27. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N, Mera T, Märten A, Hochmair MJ.
    Adv Ther; 2020 Feb 16; 37(2):759-769. PubMed ID: 31863283
    [Abstract] [Full Text] [Related]

  • 28. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.
    Lung Cancer; 2019 Jun 16; 132():126-131. PubMed ID: 31097085
    [Abstract] [Full Text] [Related]

  • 29. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
    Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators.
    Ann Oncol; 2022 Feb 16; 33(2):181-192. PubMed ID: 34839016
    [Abstract] [Full Text] [Related]

  • 30. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oizumi S, Okamoto I.
    Eur J Cancer; 2021 May 16; 149():14-22. PubMed ID: 33813328
    [Abstract] [Full Text] [Related]

  • 31. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, Kim SW, Shepherd FA, Laskin J, He Y, Akamatsu H, Theelen WSME, Su WC, John T, Sebastian M, Mann H, Miranda M, Laus G, Rukazenkov Y, Wu YL.
    Ann Oncol; 2020 Nov 16; 31(11):1536-1544. PubMed ID: 32861806
    [Abstract] [Full Text] [Related]

  • 32. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
    Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG.
    J Clin Oncol; 2024 Oct 20; 42(30):3606-3617. PubMed ID: 39047224
    [Abstract] [Full Text] [Related]

  • 33. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
    Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH.
    Target Oncol; 2020 Aug 20; 15(4):503-512. PubMed ID: 32696212
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N.
    JAMA Oncol; 2021 Mar 01; 7(3):386-394. PubMed ID: 33410885
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L, Fan J, Qian R, Luo P, Zhang J.
    Int J Cancer; 2019 Jul 01; 145(1):284-294. PubMed ID: 30613959
    [Abstract] [Full Text] [Related]

  • 36. Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.
    Minari R, Leonetti A, Gnetti L, Zielli T, Ventura L, Bottarelli L, Lagrasta C, La Monica S, Petronini PG, Alfieri R, Tiseo M.
    Anticancer Drugs; 2021 Aug 01; 32(7):758-762. PubMed ID: 33675607
    [Abstract] [Full Text] [Related]

  • 37. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
    Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Garcia Campelo R, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Fournier B, Dingemans AC, Dziadziuszko R.
    Ann Oncol; 2023 May 01; 34(5):468-476. PubMed ID: 36863484
    [Abstract] [Full Text] [Related]

  • 38. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
    Wang H, Pan R, Zhang X, Si X, Wang M, Zhang L.
    Thorac Cancer; 2020 Mar 01; 11(3):594-602. PubMed ID: 31943845
    [Abstract] [Full Text] [Related]

  • 39. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J, Jin B, Su H, Qu X, Liu Y.
    BMC Cancer; 2019 Jul 17; 19(1):702. PubMed ID: 31315676
    [Abstract] [Full Text] [Related]

  • 40. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators.
    N Engl J Med; 2017 Feb 16; 376(7):629-640. PubMed ID: 27959700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.